Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Elliott, K. J.
Right arrow Articles by Inturrisi, C. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Elliott, K. J.
Right arrow Articles by Inturrisi, C. E.
NEUROLOGY 1995;45:S66-S68
© 1995 American Academy of Neurology

Dextromethorphan shows efficacy in experimental pain (nociception) and opioid tolerance

K. J. Elliott, MD, M. Brodsky, BS, A. Hynansky, BA, K. M. Foley, MD and C. E. Inturrisi, PhD

From the Pain Service, Department of Neurology, Memorial Sloan-Kettering Cancer Center, New York, NY.
Supported in part by the VZV Foundation (K.J.E.) and NIDA grant DA01457 (C.E.I.).
Address correspondence and reprint requests to Dr Elliott, Memorial Sloan-Kettering Cancer Center, Department of Neurology, Pain Service, 1275 York Avenue, New York, NY 10021.

The oral antitussive dextromethorphan is a clinically available N-methyl-D-aspartate receptor antagonist. Dextromethorphan has analgesic efficacy in the experimental formalin test, blocks the nociceptive activation of the immediate-early gene, c-fos proto-oncogene, and prevents and reverses the development of opiate analgesic tolerance in experimental models. These data suggest that dextromethorphan should be evaluated in a controlled clinical trial for analgesic efficacy in zoster-associated neuralgia.

NEUROLOGY 1995;45(Suppl 8): S66-S68




This article has been cited by other articles:


Home page
J. Pharmacol. Exp. Ther.Home page
Y. Kolesnikov, S. Jain, R. Wilson, and G. W. Pasternak
Lack of Morphine and Enkephalin Tolerance in 129/SvEv Mice: Evidence for a NMDA Receptor Defect
J. Pharmacol. Exp. Ther., February 1, 1998; 284(2): 455 - 459.
[Abstract] [Full Text]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1995 by AAN Enterprises, Inc.